Tracking CIDP treatment with a smartwatch
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests whether a smartwatch can help monitor how well subcutaneous immunoglobulin (fSCIG) works for people with CIDP who recently switched from IVIG or plan to switch. It aims to make treatment tracking easier and more convenient.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have typical or possible typical CIDP (based on standard medical criteria).
- You are at least 18 years old.
- You are able to use a smartwatch (the study team will decide if you can).
- You have recently switched from IVIG to fSCIG (in the last 6 months) or plan to switch during the study.
- Your previous IVIG treatment was stable (confirmed by your doctor).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving immune globulin under the skin (SCIG) can help people with newly diagnosed CIDP. It may help improve muscle strength and nerve symptoms while avoiding the need for earlier IVIG/SCIG treatment.
This study tests an investigational drug called empasiprubart against standard IVIg in adults with CIDP. The goal is to see if it is safer and more effective for people who still have symptoms despite IVIg therapy.
This study looks at people with CIDP who are stable on IVIg treatment to see if we can predict when they might get worse if their treatment is adjusted. It aims to make treatment management easier and more personalized.
This study tests whether data from your own smartwatch or smartphone can help detect when your Crohn's disease or ulcerative colitis flares up. If you join, you'll use your own device, and no extra equipment will be provided.
This study is testing a new way to check inflammation in people with active IBD using non-invasive devices (like a smartwatch or sensor). It aims to find a simpler method than blood tests or stool samples, which could help manage your condition more easily.
This Phase 1 study compares IVIG given through an IV versus SCIG given under the skin, for people with CIDP. It aims to find the right weekly SCIG dose based on your current IVIG dose, which could make treatment more convenient.
Hear when a new CIDP - Chronic Inflammatory Demyelinating Polyneuropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.